British Journal of Dermatology

Papers
(The H4-Index of British Journal of Dermatology is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Classification of the cutaneous manifestations of COVID ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases926
SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases335
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*280
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*210
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*180
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases176
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial173
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases162
Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue157
The global burden of chronic urticaria for the patient and society*154
Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions133
Role of regulatory T cells in psoriasis pathogenesis and treatment127
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update123
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical119
The epidemiology of hidradenitis suppurativa*106
Aetiology and pathogenesis of hidradenitis suppurativa94
The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience91
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)89
Co‐reactivation of the human herpesvirus alpha subfamily (herpes simplex virus‐1 and varicella zoster virus) in a critically ill patient with COVID‐1974
The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case series73
Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis73
Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*69
Reviewing the global burden of acne: how could we improve care to reduce the burden?*69
Absence of images of skin of colour in publications of COVID‐19 skin manifestations69
Cutaneous lesions in a patient with COVID‐19: are they related?60
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*60
Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*60
Exploring the human hair follicle microbiome*59
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings58
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURF57
Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic56
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*55
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*54
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis53
COVID‐19 chilblain‐like lesion: immunohistochemical demonstration of SARS‐CoV‐2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction‐negative patient53
Putting the burden of skin diseases on the global map51
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label 51
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent 49
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*48
Applications and future directions for optical coherence tomography in dermatology*48
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, 46
British Association of Dermatologists guidelines for the management of people with vitiligo 202145
Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial*45
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studi45
Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis*44
Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo‐controlled, randomized, phase III clinical trial44
0.079683065414429